ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2016, 'Obstacles to prescribers' initiation early antiretroviral therapy: a barrier to achieving 90-90-90 goals', The Lancet HIV, 3, pp. e559 - e560, http://dx.doi.org/10.1016/S2352-3018(16)30172-2
,2016, 'Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV', Osteoporosis International, 27, pp. 1737 - 1745, http://dx.doi.org/10.1007/s00198-015-3432-3
,2015, 'The HIV care cascade: A systematic review of data sources, methodology and comparability', Journal of the International AIDS Society, 18, http://dx.doi.org/10.7448/IAS.18.1.20634
,2015, 'Clinic network collaboration and patient tracing to maximize retention in HIV care', PLoS ONE, 10, http://dx.doi.org/10.1371/journal.pone.0127726
,2015, 'Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study', PLoS Medicine, 12, pp. e1001809, http://dx.doi.org/10.1371/journal.pmed.1001809
,2014, 'Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 3, http://dx.doi.org/10.1161/JAHA.114.000844
,2014, 'Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine', PLoS ONE, 9, pp. e94858, http://dx.doi.org/10.1371/journal.pone.0094858
,2014, 'Factors associated with D-dimer levels in HIV-infected individuals', PLoS ONE, 9, http://dx.doi.org/10.1371/journal.pone.0090978
,2014, '90-90-90: How do we get there?', The Lancet HIV, 1, pp. e10 - e11, http://dx.doi.org/10.1016/S2352-3018(14)70017-7
,2013, 'Outcomes of Antiretroviral Therapy in Vietnam: Results from a National Evaluation', PLoS ONE, 8, http://dx.doi.org/10.1371/journal.pone.0055750
,2013, 'Platelet count kinetics following interruption of antiretroviral treatment', AIDS, 27, pp. 59 - 68, http://dx.doi.org/10.1097/QAD.0b013e32835a104d
,2013, 'Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study', PLoS ONE, 8, pp. e56249, http://dx.doi.org/10.1371/journal.pone.0056249
,2012, 'Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine', PLoS ONE, 7, pp. e38377, http://dx.doi.org/10.1371/journal.pone.0038377
,2012, 'The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV.', AIDS, 26, pp. 2337 - 2344, http://dx.doi.org/10.1097/QAD.0b013e32835ab213
,2011, 'Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT)', HIV Medicine, 12, pp. 219 - 227, http://dx.doi.org/10.1111/j.1468-1293.2010.00875.x
,2011, 'Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or Abacavir-Lamivudine', PLoS One, 6, pp. Article number e26885, http://dx.doi.org/10.1371/journal.pone.0026885
,2010, 'Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial', AIDS, 24, pp. 2657 - 2663
,2010, 'The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters', AIDS, 24, pp. 353 - 363
,2009, 'Interruption of antiretroviral therapy is associated with increased plasma cystatin C', AIDS, 23, pp. 71 - 82, http://dx.doi.org/10.1097/QAD.0b013e32831cc129
,2009, 'Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection', Journal of Infectious Diseases, 200, pp. 973 - 983, http://dx.doi.org/10.1086/605447
,2009, 'Continuous antiretroviral therapy decreases bone mineral density', AIDS, 23, pp. 1519 - 1529
,2009, 'Interleukin-2 therapy in patients with HIV infection.', New England Journal of Medicine, 361, pp. 1548 - 1559
,2008, 'The rise of infectious syphilis in Victoria and the impact of enhanced clinical testing', Australian and New Zealand Journal of Public Health, 32, pp. 38 - 42, http://dx.doi.org/10.1111/j.1753-6405.2008.00164.x
,2008, '2-Day versus 5-day famciclovir as treatment of recurrences of genital herpes: Results of the FaST study (Sexual Health (2008) 5, 3, (219-225))', Sexual Health, 5, pp. 379, http://dx.doi.org/10.1071/SH08013_CO
,2008, '2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: Results of the FaST study', Sexual Health, 5, pp. 219 - 225
,2008, 'Effect of Rosiglitazone on Peroxisome Proliferator-Activated Receptor gamma Gene Expression in Human Adipose Tissue Is Limited by Antiretroviral Drug-Induced Mitochondrial Dysfunction', Journal of Infectious Diseases, 198, pp. 1794 - 1803
,2008, 'Inferior clinical outcome of the CD4(+) cell count guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4(+) cell counts and HIV RNA levels during follow-up', Journal of Infectious Diseases, 197, pp. 1145 - 1155, http://dx.doi.org/10.1086/529523
,2008, 'Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study', Journal of Infectious Diseases, 197, pp. 1133 - 1144, http://dx.doi.org/10.1086/586713
,2008, 'Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy - a randomized trial', Annals of Internal Medicine, 149, pp. 289 - W62
,2008, 'Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen', AIDS, 22, pp. 2279 - 2289
,2007, 'A new surveillance system for monitoring HIV infection in Victoria, Australia', Sexual Health, 4, pp. 195 - 199, http://dx.doi.org/10.1071/SH07011
,2007, 'Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2', HIV Medicine, 8, pp. 112 - 123, http://dx.doi.org/10.1111/j.1468-1293.2007.00440.x
,2006, 'Evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants', HIV Clinical Trials, 7, pp. 70 - 85
,2005, 'Syphilis: Back on the rise, but not unstoppable', Medical Journal of Australia, 183, pp. 172 - 173, http://dx.doi.org/10.5694/j.1326-5377.2005.tb06985.x
,2005, 'Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database', HIV Medicine, 6, pp. 155 - 163
,2004, 'Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes', Lancet, 364, pp. 51 - 62, http://dx.doi.org/10.1016/S0140-6736(04)16589-6
,2003, 'Screening for Neisseria gonorrhoeae and Chlamydia trachomatis in Men Who Have Sex with Men at Male-only Saunas', Sexually Transmitted Diseases, 30, pp. 886 - 889, http://dx.doi.org/10.1097/01.OLQ.0000099160.26205.22
,2003, 'HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy', HIV Medicine, 4, pp. 241 - 249
,2002, 'Rates of combination antiretroviral treatment change in Australia, 1997-2000', HIV Medicine, 3, pp. 28 - 36
,2001, 'Sexually transmitted diseases in HIV-1-infected patients', LANCET, 357, pp. 1533 - 1534, http://dx.doi.org/10.1016/S0140-6736(00)04693-6
,2001, 'Time trends in antiretroviral treatment use in Australia', Venereology - the Interdisciplinary International Journal of Sexual Health, 14, pp. 162 - 168
,